EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Primary per cutaneous vaccination


Journal of Infectious Diseases 135(1): 145-154
Primary per cutaneous vaccination
In an investigation of the antigenicity and reactogenicity of 4 smallpox vaccines, 786 children received primary percutaneous vaccination with vaccine in 1 of 3 concentrations, 106, 107 or 108 pock-forming units/ml. Dose-response curves indicated that the 3 licensed vaccines (New York City Board of Health strains grown in calf lymph or chorioallantoic membrane, and the Lister vaccine) had similar potencies, but the CV-1 strain was .apprx. 10-fold less infectious. CV-1 also produced smaller skin lesions than the other 3 vaccines, and the incidence of fever in CV-1 vaccinees who developed major reactions or serum antibody was not significantly different from that in children in all vaccine groups with no evidence of take. Hemagglutination-inhibiting antibody was consistently seen in individuals who received potent New York City and Lister vaccines, and neutralizing antibody was induced in 82%-85% of children in this group who had some evidence of take (production of hemagglutination-inhibiting antibody or major reaction). Only 30% of CV-1 vaccinees with takes produced neutralizing antibody. Minor complications occurred in all groups, but most often in children who received the New York City strains.


Accession: 006184010



Related references

Standard per cutaneous re vaccination of children who received primary sub cutaneous vaccination. Journal of Infectious Diseases 135(1): 176-182, 1977

Standard per cutaneous re vaccination of children who received primary per cutaneous vaccination. Journal of Infectious Diseases 135(1): 155-166, 1977

Smallpox vaccination by intradermal jet injection. 2. Cutaneous and serological responses to primary vaccination in children. Bulletin of the World Health Organization 41(6): 761-769, 1969

Small pox vaccination by intra dermal jet injection part 2 cutaneous and serological responses to primary vaccination in children. Bulletin of the World Health Organization 4(6): 761-769, 1969

Cutaneous complications of primary vaccination against smallpox. Tijdschrift Voor Sociale Geneeskunde 40: 641-644, 1962

Intra-cutaneous vaccination of guinea pigs against anthrax by primary vaccine alone. Compt Rend Soc Biol 95(32): 1138-1139, 1926

Primary vaccination against smallpox after preliminary vaccination with the attenuated vaccinia virus strain MVA and the use of a new "vaccination stamp". Munchener Medizinische Wochenschrift 115(35): 1471-1473, 1973

The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S├ęzary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology 157(6): 1205-1211, 2007

The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology 157(6): 1205-1211, 2007

Influenza vaccination of primary healthcare physicians may be associated with vaccination in their patients: a vaccination coverage study. Bmc Family Practice 16(): 44-44, 2016